Skip to main content
Top
Published in: Breast Cancer Research 1/1999

01-12-1999 | Paper Report

Liposome-plasmid complexes encoding angiostatin and endostatin inhibit breast cancer in nude mice

Author: Richard de Boer

Published in: Breast Cancer Research | Issue 1/1999

Login to get access

Excerpt

Angiogenesis has been shown to be crucial for both tumor growth and metastasis. Preventing angiogenesis with antiangiogenic factors is an obvious therapeutic strategy. Two antiangiogenic factors that have been identified are angiostatin and endostatin. Derived from parent proteins (plasminogen and collagen XVIII respectively) these polypeptides inhibit endothelial cell proliferation while having no obvious toxicity although delivery of these agents is difficult, and usually requires prolonged infusions. An alternative delivery method is gene therapy transfer. Standard gene therapy uses viral vectors; however, there are safety and toxicity issues surrounding the use of viral vectors. This study examined whether liposomes complexed to plasmids encoding angiostatin or endostatin could successfully inhibit angiogenesis and the growth of MDA-MB-435 tumors implanted in the mammary fat pads of nude mice. …
Literature
1.
go back to reference Chen Q-R, Kumar D, Stass SA, Mixson AJ : Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res. 1999, 59: 3308-3312.PubMed Chen Q-R, Kumar D, Stass SA, Mixson AJ : Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res. 1999, 59: 3308-3312.PubMed
Metadata
Title
Liposome-plasmid complexes encoding angiostatin and endostatin inhibit breast cancer in nude mice
Author
Richard de Boer
Publication date
01-12-1999
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/1999
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr-1999-66602

Other articles of this Issue 1/1999

Breast Cancer Research 1/1999 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine